Subcutaneous Immunotherapy: Better Life for Cancer Patients
Administering immunotherapy via subcutaneous infections could save clinicians time and money and patients may prefer it.
Source: medscape.com
Federico Cappuzzo News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Federico Cappuzzo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Federico Cappuzzo Today - Breaking & Trending Today
Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab
Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.
Source: onclive.com
Dr Cappuzzo on Findings from the RATIONALE-315 Trial in Resectable NSCLC
Federico Cappuzzo, MD, discusses findings from the phase 3 RATIONALE-315 trial in patients with resectable non–small cell lung cancer.
Source: onclive.com
RATIONALE-315 Data Support Perioperative Tislelizumab Plus Neoadjuvant Chemo in Resectable NSCLC
Neoadjuvant tislelizumab plus platinum-based doublet chemotherapy followed by surgery and adjuvant tislelizumab demonstrated efficacy in resectable non–small cell lung cancer.
Source: onclive.com
Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages On
The question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both remains a hot topic of debate.
Source: medscape.com